Intermittent therapy with 6-mercaptopurine (NSC-755) and methotrexate (NSC-740) given intravenously to adults with acute leukemia.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D001853:Bone Marrow / Q000187:drug effects; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000401:mortality; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy / Q000401:mortality; D015122:Mercaptopurine / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D011379:Prognosis; D012075:Remission, Spontaneous; D013997:Time Factors
D000305:Adrenal Cortex Hormones; D015122:Mercaptopurine; D008727:Methotrexate